Eisai Announces FDA Approval of Fycompa in Pediatric Patients as Young as 4 Years Old for the Treatment of Partial-Onset Seizures

WOODCLIFF LAKE, N.J., Sept. 28, 2018 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) expanded the indication of its antiepileptic drug Fycompa (perampanel) CIII for monotherapy and adjunctive use in...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news